Cellero was formed through a merger between Astarte Biologics of Bothell, WA and Key Biologics of Memphis, TN in September 2019. Edit: In August 2020, Cellero was acquired by Charles River laboratories. In February 2021, Cellero was integrated into Hemacare, a Charles River Company.Responsible for direction and conduct of:- Product development, planning, quality testing and production of all Astarte's product line of immune cell products for research, including PBMC and their individual components, specialty cell types e.g., dendritic cells, antigen-specific T cells, T regulatory cells, CD34+ cells etc.- Research services including development of cell-based assays and analysis of client's agents using cell-based assays (e.g., effect on antigen-specific T cell response, Treg function, monocyte activation etc.), development of antigen-specific T cells etc.- A team member of Cellero leadership team responsible for planning company vision and strategic planning.

Responsible for direction and conduct of:- Product development, planning, quality testing and production of all Astarte's product line of immune cell products for research, including PBMC and their individual components, specialty cell types e.g., dendritic cells, antigen-specific T cells, T regulatory cells, CD34+ cells etc.- Research services including development of cell-based assays and analysis of client's agents using cell-based assays (e.g., effect on antigen-specific T cell response, Treg function, monocyte activation etc.), development of antigen-specific T cells etc.

Research and Consultancy in Biotechnology

Responsible for the overall strategic direction and oversight of creating, implementing and reporting of manufacturing of the investigational product or devise.• Planned and conducted process development and qualification for a GMP production of a cellular cancer vaccine for clinical testing• Major contributor in the preparation of different portions of a successful United States IND submission• Established relationship with a contract manufacturing and a contract immune monitoring laboratory

* Leads the research team in the development of “second generation” dendritic cell-based vaccines for solid tumors. Research scope includes: generation of clinical-grade cellular product, assay developments for quality testing and immune monitoring strategies* Heads the team responsible for the design of testing and production of a dendritic cell-based vaccine for a pilot clinical trial sponsored by the company’s Asian subsidiary in Manila, Philippines* Contributed to the foundation intellectual property and publication (one patent published)

Responsible for research, supervision and technology transfer of basic and product-oriented studies in immunology and cell biology.  Study area included: human dendritic cell basic biology, in vitro generation, antigen-loading, maturation, pre-clinical dendritic cell-based cancer vaccine studies, and assay developments. * Awarded patents: "Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy."  USA: 5,788,963; Australia:723607; New Zealand:315441 and "Generation of dendritic cells from monocytic dendritic precursor cells with GM-CSF in the absence of additional cytokines USA 8,389,278 (5 March 2013)* Designed and submitted SBIR grant proposals for pre-clinical research in the feasibility of dendritic cell-based therapy of brain neoplasm * Conceived, designed, and developed a novel device/technology for dendritic cell precursor isolation in an automated and closed system* Collaborated with Manufacturing and Process Development in technology transfers from R&D* Published over 20 scientific articles